Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression

References

• van Dongen JJ, Seriu T, Panzer-Grümayer ER, . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731–1738.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Howe K, Langabeer S, . Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996;10:61–66.
   PubMed Web of Science ®Google Scholar
• Bahia DM, Yamamoto M, Chauffaille Mde L, . Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance. Haematologica 2001;86:801–806.
   PubMed Web of Science ®Google Scholar
• Kern W, Bacher U, Haferlach C, . The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010;23:379–390.
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078–3085.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, López-Berges C, . Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746–1751.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Gattei V, . The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006;20: 1783–1789.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Caligiuri MA, Döhner H, . Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with inv(16) acute myeloid leukemia. Leukemia 2001;15:1072–1080.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Weisser M, Schoch C, . New score predicting for prognosis in PML-RARA +, AML1-ETO +, or CBFBMYH11 + acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746–2755.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004;112:79–84.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, . Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.
   PubMed Web of Science ®Google Scholar
• Chou WC, Tang JL, Wu SJ, . Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007;21:998–1004.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Kern W, Tschulik C, . Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220–2231.
   PubMed Web of Science ®Google Scholar
• Krönke J, Schlenk RF, Jensen K-O, . Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011;29:2709–2716.
   PubMed Web of Science ®Google Scholar
• Papadaki C, Dufour A, Seibl M, . Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144:517–523.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kiyoi H, Ozeki K, . Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854–2861.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Yamagami T, . Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267–2278.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, . Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074–3080.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Falini B, Martelli MP, Bolli N, . Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109–1120.
   PubMed Web of Science ®Google Scholar
• Miglino M, Colombo N, Pica G, . WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma 2011;52: 1961–1969.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, . Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2009;113:1875–1891.
   PubMed Web of Science ®Google Scholar
• Corbacioglu A, Scholl C, Schlenk RF, . Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010;28:3724–3729.
   PubMed Web of Science ®Google Scholar